Techn ology Regains Compliance with Nasdaq Continued Listing Requirements

Techn ology Regains Compliance with Nasdaq Continued Listing Requirements

TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL;

NXLIW) announced that the Company received notice from The Nasdaq Stock Market ("Nasdaq") on April 23, 2024, notifying the

Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2).

White, CEO of Nexalin, stated, "We remain committed to our mission of revolutionizing the treatment of mental health and neurological

conditions through our safe, non-invasive, and drug-free neurostimulation technology. We believe our Nasdaq listing provides us with

much greater exposure within the investment community, which is particularly important given the positive ongoing developments and anticipated

upcoming milestones. I would like to extend my gratitude to our shareholders for your continued support and confidence in Nexalin's

vision and capabilities."

Nexalin Technology, Inc.

designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's

products are believed to be non-invasive and undetectable to the human body and developed to provide relief to those afflicted with mental

health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation

medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the

deeper penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects.

The Nexalin Gen-2 15 milliamp neurostimulation device was recently approved in Oman and China. Additional information about the Company

is available at: https://nexalin.com.

press release contains statements that constitute "forward-looking statements," These statements relate to future events

or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of

future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that

Nexalin or its management "believes", "expects", "anticipates", "plans", "intends"

and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual

events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking

statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the

Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with

the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking

statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date

hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after

the date of this release, except as required by law.